193 reports of this reaction
1.9% of all VIBEGRON reports
#12 most reported adverse reaction
URINARY INCONTINENCE is the #12 most commonly reported adverse reaction for VIBEGRON, manufactured by Sumitomo Pharma America, Inc.. There are 193 FDA adverse event reports linking VIBEGRON to URINARY INCONTINENCE. This represents approximately 1.9% of all 10,281 adverse event reports for this drug.
VIBEGRON has an overall safety score of 35 out of 100. Patients taking VIBEGRON who experience urinary incontinence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URINARY INCONTINENCE is a less commonly reported adverse event for VIBEGRON, but still significant enough to appear in the safety profile.
In addition to urinary incontinence, the following adverse reactions have been reported for VIBEGRON:
URINARY INCONTINENCE has been reported as an adverse event in 193 FDA reports for VIBEGRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
URINARY INCONTINENCE accounts for approximately 1.9% of all adverse event reports for VIBEGRON, making it a notable side effect.
If you experience urinary incontinence while taking VIBEGRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.